MorphoSys Share Price Performance
In the first quarter the pharmaceutical and biotechnology sector was under pressure partly due to ongoing discussions about what impact the reform of the US healthcare system will have on the sector. The NASDAQ Biotechnology Index fell by 9.5%, the TecDAX by 4.6%, and the DAX subsector Biotechnology Performance Index decreased by 5.9%. During the same period MorphoSys’s share price experienced a decrease of 32%. By comparison, a basket of international antibody companies (Source: BioCentury) increased by 0.8%.
The MorphoSys Share (January 2, 2009 = 100%)
